Pages that link to "Q33321788"

The following pages link to High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. (Q33321788):

Displaying 11 items.

• Neoadjuvant therapy for pancreas cancer: past lessons and future therapies (Q27004292) (← links)
• Systemic therapies for pancreatic cancer--the role of pharmacogenetics (Q27021716) (← links)
• Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer (Q34414547) (← links)
• Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer (Q35202502) (← links)
• Drug metabolism and pancreatic cancer (Q37542844) (← links)
• Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy (Q38633683) (← links)
• Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer (Q43195002) (← links)
• Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group) (Q43598640) (← links)
• Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer (Q44359483) (← links)
• Relationship Between Gene Expression of 5-Fluorouracil Metabolic Enzymes and 5-Fluorouracil Sensitivity in Primary Cancer Cells Isolated from Malignant Ascites (Q83141665) (← links)
• Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S‐1‐based adjuvant chemotherapy after surgical resection (Q84021612) (← links)